Suven Life Sciences Limited (NSE:SUVEN)
India · Delayed Price · Currency is INR 291.02
+0.83 (0.29%)
Jul 18, 2025, 3:30 PM IST
Suven Life Sciences Revenue
In the fiscal year ending March 31, 2025, Suven Life Sciences had annual revenue of 66.56M INR, down -43.08%. Suven Life Sciences had revenue of 14.67M in the quarter ending March 31, 2025, a decrease of -38.50%.
Revenue
66.56M
Revenue Growth
-43.08%
P/S Ratio
949.68
Revenue / Employee
472.04K
Employees
141
Market Cap
63.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 66.56M | -50.37M | -43.08% |
| Mar 31, 2024 | 116.93M | -19.02M | -13.99% |
| Mar 31, 2023 | 135.95M | 16.44M | 13.76% |
| Mar 31, 2022 | 119.51M | -21.23M | -15.08% |
| Mar 31, 2021 | 140.73M | -6.32M | -4.30% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Mankind Pharma | 122.07B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Glenmark Pharmaceuticals | 134.35B |
Suven Life Sciences News
- 6 months ago - Suven Life Sciences shares surge over 8% after clinical trial update - Business Upturn
- 6 months ago - Suven Life Sciences initiates Phase-1 clinical trial for SUVN-I6107 - Business Upturn